reports
- Francesca Ferragina
- Michiel Vereycken
Retail Real Estate Update/Looking for defensiveness
The retail segment outperformed in 2025 driven by strong operational momentum. Fundamentals remain strong but the Middle East conflict is a risk due to its impact on inflation/rates, energy prices and purchasing power. That is why we favour defensive names: we reward food exposure, convenience centres and low OCRs mixed with healthy balance sheets. Retail Estates ticks all the boxes. Eurocommercial has the cheapest valuation (41.5% discount to 2026F NAV) and its dominant shopping centres have de...
Nextensa NV/SA: Information on the total number of voting rights an...
Nextensa NV/SA: Information on the total number of voting rights and shares PRESS RELEASE REGULATED INFORMATION Brussels, 31 March 2026, 5:55 PM Nextensa NV/SA: Information on the total number of voting rights and shares In application of article 15 of the Law of 2 May 2007 on disclosure of major shareholdings, Nextensa (the 'Company') announces the following information following the loss of double voting rights attached to registered shares. Situation on 31 March 2026: Total capital : EUR 111,856,017.40 Total nu...
Nextensa SA: Informations relatives au nombre total de droits de vo...
Nextensa SA: Informations relatives au nombre total de droits de vote et d'actions COMMUNIQUÉ DE PRESSE INFORMATION RÉGLEMENTÉE Bruxelles, 31 mars 2026, 17h55 Nextensa SA: Informations relatives au nombre total de droits de vote et d'actions En application de l'article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nextensa (la ‘Société’) communique les informations suivantes suite à la perte des droits de vote double attachés aux actions nominatives. Situation au 31 mars 2026 : Total du...
Nextensa NV: Informatie betreffende het totale aantal stemrechten en ...
Nextensa NV: Informatie betreffende het totale aantal stemrechten en aandelen PERSBERICHT GEREGLEMENTEERDE INFORMATIEBrussel, 31 maart 2026, 17u55 Nextensa NV: Informatie betreffende het totale aantal stemrechten en aandelen In toepassing van artikel 15 van de wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen, maakt Nextensa (de ‘Vennootschap’) de volgende informatie bekend naar aanleiding van het verlies van het dubbel stemre...
- Jacob Mekhael
MaaT Pharma FY25 update confirms mid-2026 EMA decision timing for MaaT...
MaaT reported FY25 results which show increasing revenues from MaaT013's early access program (only billable in France) of € 4.5m (FY24: € 3.2m) in aGvHD. In addition, the company confirmed its cash runway guidance to August 2026, which funds the company beyond the expected EMA regulatory decision for MaaT013 in aGvHD expected in mid-2026. Pipeline wise, we note that a few timelines have shifted, with phase 2 data for MaaT013 + checkpoint inhibitors in metastatic melanoma now expected in 1H26 (v...
- Jacob Mekhael
Inventiva FY25 results narrow lani phase 3 MASH readout timing to 4Q26
Inventiva's FY25 results come with narrowed timeline guidance for the topline results from the phase 3 (NATiV3) trial of lanifibranor in MASH which is expected in 4Q26 (previously 2H26). We believe this readout is de-risked by strong phase 2b data, and with oral dosing and clean safety (limited GI side effects), lanifibranor is well positioned to capture a meaningful share of the MASH commercial opportunity. Inventiva confirmed its cash runway guidance to middle of 1Q27, beyond the key milestone...
- Guy Sips
- Jacob Mekhael
- Mathijs Geerts Danau
- Wim Lewi
Inventiva reports 2025 full year results and provides a business updat...
Inventiva reports 2025 full year results and provides a business update Revenues of €4.5 million for the full year of 2025Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits1 as at December 31, 2025Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million2)Cash runway expected until the middle of the first quarter of 20273Completed the sale of odiparcil with potential milestone payments of up to $90 million and potential royalties on future net sales, if approvedTopline results of NATiV3 Phase 3 clinical tr...
Inventiva publie ses résultats financiers annuels 2025 et fait le poi...
Inventiva publie ses résultats financiers annuels 2025 et fait le point sur son activité Chiffre d'affaires de 4,5 millions d'euros pour l’année 2025Trésorerie et équivalents de trésorerie à 99,3 millions d’euros et 131,6 millions d'euros en dépôts à court terme1 au 31 décembre 2025Réalisation d'une offre au public aux États-Unis pour un produit brut d'environ 172,5 millions de dollars (149 millions d'euros2)Horizon de trésorerie prévu jusqu’au milieu du premier trimestre 20273Finalisation de la cession d'odiparcil avec des paiements d’étapes potentiels pouvant atteindre 90 millions de dol...
- Jacob Mekhael
Hyloris FY25 results hold no major surprises
Hyloris reported FY25 results with a cash position of € 13.8m (YE24: € 23.6m), and revenue of € 7.2m (FY24: € 8.5m), driven by increased royalties but offset by lower milestone payments. Hyloris is yet to receive income related to commercialisation of Maxigesic IV in the US as the launch has been paused and restarted. The company did not provide specific cash runway guidance, but believes it has funding for development and strategic growth. € 6 TP and Hold maintained.
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Mathijs Geerts Danau
- Thomas Couvreur
- Wim Hoste
- Lynn Hautekeete
- Wim Lewi
WEB WAREHOUSES ESTATES BELGIUM S.C.A.
LEAS LEASINVEST REAL ESTATE SCA
IMMO COMPAGNIE IMMOBILIERE DE BELGIQUE SA
RET RETAIL ESTATES NV
ELI ELIA GROUP SA/NV
MONT MONTEA SCA
AED AEDIFICA SA
QRF QRF COMM
CPINV CARE PROPERTY INVEST SA
ATEB ATENOR S.A.
ASC ASCENCIO SCA
ARG ARGAN SA
VGP VGP NV
TINC TINC COMM. VA
WDP WAREHOUSES DE PAUW SCA
ECMPA EUROCOMMERCIAL PROPERTIES NV
CTPNV CTP NV
HOMI HOME INVEST BELGIUM
SHUR SHURGARD SELF STORAGE LIMITED
ENRGY ENERGYVISION
Inventiva Schedules the Publication and Presentation of its 2025 Full-...
Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results Daix (France), New York (United States), March 23, 2026 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that it will release its 2025 full-year financial results on Monday, March 30, 2026, after market close in the United States. Inventiva’s management will hold a conference call in English, follow...
Inventiva annonce la publication et la présentation de ses résultats f...
Inventiva annonce la publication et la présentation de ses résultats financiers annuels 2025 Daix (France), New York (États-Unis), le 23 mars 2026 – (Euronext Paris et Nasdaq : ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une thérapie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), annonce aujourd'hui qu'elle publiera ses résultats financiers annuels 2025 le lundi 30 mars 2026, après la clôture des marchés américains. La direction d'Inventiva tiendra une conférence téléphonique en ...
- Lynn Hautekeete
- Wim Lewi
LEAS LEASINVEST REAL ESTATE SCA
XIOR XIOR STUDENT HOUSING N.V.
COFB COFINIMMO SA
IMMO COMPAGNIE IMMOBILIERE DE BELGIQUE SA
RET RETAIL ESTATES NV
ELI ELIA GROUP SA/NV
MONT MONTEA SCA
AED AEDIFICA SA
QRF QRF COMM
CPINV CARE PROPERTY INVEST SA
ATEB ATENOR S.A.
ASC ASCENCIO SCA
ARG ARGAN SA
VGP VGP NV
TINC TINC COMM. VA
WDP WAREHOUSES DE PAUW SCA
ECMPA EUROCOMMERCIAL PROPERTIES NV
CTPNV CTP NV
HOMI HOME INVEST BELGIUM
SHUR SHURGARD SELF STORAGE LIMITED
ENRGY ENERGYVISION
- Lynn Hautekeete
Nextensa Model update after FY25 results, hold reiterated
We update our model after the FY25 results and include the new guidance on the Bel Tower project and Proximus HQ into our estimates. The Proximus HQ project moved from development projects to investment properties, resulting in a higher debt ratio as we don't factor in an immediate exit. We accelerate disposals of standing assets into our model from €50.0m to €100.0m per annum to counterbalance the €565m cash drain from developments. We downgraded Nextensa from Accumulate to Hold ahead of the re...
- Guy Sips
- Hilde Van Boxstael
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Wim Hoste
- Wim Lewi
- ING Helpdesk
Benelux Morning Notes
Aedifica and Cofinimmo: Exchange offer complete and new board members appointed. D'Ieteren: Change in CEO at Moleskine, preview FY25. Euronext: Positive volume momentum continues. Retail Estates: €27m retail park development. Staffing: French January trend softer on tough comps, February outlook better
- Guy Sips
- Michiel Declercq
- Wim Lewi
Citi chooses The Rock in Cloche d’Or
Citi chooses The Rock in Cloche d’Or PRESS RELEASE NON-REGULATED INFORMATIONLuxembourg, March 4, 2026, 17:55 PM Citi chooses The Rock in Cloche d’Or Luxembourg March 4, 2026 - Nextensa, in partnership with Promobe through their joint venture Grossfeld, announces that Citi (bank) has signed a long-term lease agreement for office space in The Rock, a new landmark office building located in the Cloche d’Or district of Luxembourg. ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.